State Street’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.1M | Buy |
562,106
+38,391
| +7% | +$515K | ﹤0.01% | 2792 |
|
|
2025
Q4 | $8.26M | Buy |
523,715
+51,723
| +11% | +$657K | ﹤0.01% | 2740 |
|
|
2025
Q3 | $5.65M | Buy |
471,992
+1,722
| +0.4% | +$13.8K | ﹤0.01% | 2954 |
|
|
2025
Q2 | $3.56M | Buy |
470,270
+14,876
| +3% | +$89.5K | ﹤0.01% | 3081 |
|
|
2025
Q1 | $2.51M | Sell |
455,394
-5,590
| -1% | -$34.5K | ﹤0.01% | 3164 |
|
|
2024
Q4 | $2.65M | Buy |
460,984
+11,009
| +2% | +$106K | ﹤0.01% | 3225 |
|
|
2024
Q3 | $4.66M | Buy |
449,975
+27,147
| +6% | +$355K | ﹤0.01% | 3003 |
|
|
2024
Q2 | $5.48M | Sell |
422,828
-1,137
| -0.3% | -$15.3K | ﹤0.01% | 2889 |
|
|
2024
Q1 | $7.4M | Sell |
423,965
-1,675
| -0.4% | -$22.2K | ﹤0.01% | 2747 |
|
|
2023
Q4 | $4.01M | Sell |
425,640
-24,518
| -5% | -$228K | ﹤0.01% | 3046 |
|
|
2023
Q3 | $5.03M | Sell |
450,158
-1,068,093
| -70% | -$17.2M | ﹤0.01% | 2915 |
|
|
2023
Q2 | $32.5M | Buy |
1,518,251
+317,315
| +26% | +$9.35M | ﹤0.01% | 1926 |
|
|
2023
Q1 | $48.6M | Sell |
1,200,936
-311,256
| -21% | -$14.9M | ﹤0.01% | 1669 |
|
|
2022
Q4 | $70.3M | Buy |
1,512,192
+134,775
| +10% | +$6.14M | ﹤0.01% | 1408 |
|
|
2022
Q3 | $71.4M | Sell |
1,377,417
-322,011
| -19% | -$18.8M | ﹤0.01% | 1341 |
|
|
2022
Q2 | $80.3M | Buy |
1,699,428
+390,842
| +30% | +$21.2M | ﹤0.01% | 1323 |
|
|
2022
Q1 | $93.1M | Buy |
1,308,586
+181,517
| +16% | +$11.8M | ﹤0.01% | 1341 |
|
|
2021
Q4 | $84.3M | Buy |
1,127,069
+54,887
| +5% | +$4.31M | ﹤0.01% | 1436 |
|
|
2021
Q3 | $60.9M | Buy |
1,072,182
+18,107
| +2% | +$895K | ﹤0.01% | 1659 |
|
|
2021
Q2 | $46.4M | Sell |
1,054,075
-44,049
| -4% | -$2.16M | ﹤0.01% | 1903 |
|
|
2021
Q1 | $54.2M | Sell |
1,098,124
-75,116
| -6% | -$3.75M | ﹤0.01% | 1688 |
|
|
2020
Q4 | $49.4M | Buy |
1,173,240
+209,722
| +22% | +$9.23M | ﹤0.01% | 1649 |
|
|
2020
Q3 | $44.1M | Sell |
963,518
-95,578
| -9% | -$4.63M | ﹤0.01% | 1550 |
|
|
2020
Q2 | $53.2M | Buy |
1,059,096
+151,172
| +17% | +$7.82M | ﹤0.01% | 1428 |
|
|
2020
Q1 | $46.7M | Buy |
907,924
+77,071
| +9% | +$4.11M | ﹤0.01% | 1301 |
|
|
2019
Q4 | $51.3M | Sell |
830,853
-52,183
| -6% | -$3.24M | ﹤0.01% | 1505 |
|
|
2019
Q3 | $53.1M | Buy |
883,036
+22,678
| +3% | +$1.68M | ﹤0.01% | 1403 |
|
|
2019
Q2 | $72.6M | Sell |
860,358
-60,095
| -7% | -$5.41M | 0.01% | 1243 |
|
|
2019
Q1 | $87.9M | Sell |
920,453
-40,626
| -4% | -$3.64M | 0.01% | 1089 |
|
|
2018
Q4 | $68.1M | Sell |
961,079
-238,088
| -20% | -$18.3M | 0.01% | 1154 |
|
|
2018
Q3 | $102M | Buy |
1,199,167
+428,868
| +56% | +$43M | 0.01% | 1062 |
|
|
2018
Q2 | $89.3M | Buy |
770,299
+12,500
| +2% | +$1.25M | 0.01% | 1117 |
|
|
2018
Q1 | $61.3M | Buy |
757,799
+35,903
| +5% | +$2.76M | 0.01% | 1297 |
|
|
2017
Q4 | $42.4M | Buy |
721,896
+897
| +0.1% | +$44.9K | ﹤0.01% | 1529 |
|
|
2017
Q3 | $33.7M | Buy |
720,999
+34,952
| +5% | +$1.4M | ﹤0.01% | 1643 |
|
|
2017
Q2 | $24.7M | Sell |
686,047
-62,777
| -8% | -$2.01M | ﹤0.01% | 1839 |
|
|
2017
Q1 | $23.1M | Buy |
748,824
+180,586
| +32% | +$5.62M | ﹤0.01% | 1830 |
|
|
2016
Q4 | $19M | Buy |
568,238
+236,871
| +71% | +$6.79M | ﹤0.01% | 1935 |
|
|
2016
Q3 | $8.82M | Sell |
331,367
-320,894
| -49% | -$7.45M | ﹤0.01% | 2253 |
|
|
2016
Q2 | $14.4M | Buy |
652,261
+70,709
| +12% | +$1.85M | ﹤0.01% | 1986 |
|
|
2016
Q1 | $17.1M | Sell |
581,552
-3,008
| -0.5% | -$83.7K | ﹤0.01% | 1832 |
|
|
2015
Q4 | $19.3M | Sell |
584,560
-311,053
| -35% | -$10.1M | ﹤0.01% | 1737 |
|
|
2015
Q3 | $32.4M | Buy |
895,613
+52,503
| +6% | +$2.25M | ﹤0.01% | 1420 |
|
|
2015
Q2 | $37.9M | Buy |
843,110
+64,582
| +8% | +$2.51M | ﹤0.01% | 1430 |
|
|
2015
Q1 | $23.8M | Buy |
778,528
+256,754
| +49% | +$9.99M | ﹤0.01% | 1733 |
|
|
2014
Q4 | $26.5M | Buy |
521,774
+397,077
| +318% | +$17.8M | ﹤0.01% | 1598 |
|
|
2014
Q3 | $4.93M | Buy |
124,697
+1,900
| +2% | +$75.7K | ﹤0.01% | 2556 |
|
|
2014
Q2 | $5.29M | Buy |
122,797
+72,153
| +142% | +$2.75M | ﹤0.01% | 2564 |
|
|
2014
Q1 | $2.03M | Buy |
50,644
+7,844
| +18% | +$285K | ﹤0.01% | 3059 |
|
|
2013
Q4 | $1.17M | Buy |
42,800
+8,603
| +25% | +$208K | ﹤0.01% | 3227 |
|
|
2013
Q3 | $783K | Buy |
+34,197
| New | +$653K | ﹤0.01% | 3289 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
State Street's ENTA Position: Q1 2026 in Review
State Street increased its Enanta Pharmaceuticals (ENTA) stake by 7.3% in Q1 2026, buying an estimated $515K and bringing the position to 562,106 shares worth $7.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2792.
State Street first reported a position in ENTA in Q3 2013 and has held it in 51 quarters since. The position peaked at $102M in Q3 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- State Street held 562,106 shares of Enanta Pharmaceuticals worth $7.1M as of Q1 2026.
- State Street bought 38,391 Enanta Pharmaceuticals shares in Q1 2026, an estimated $515K.
- Enanta Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2792 holding.
- State Street first reported a position in Enanta Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
- State Street's Enanta Pharmaceuticals position peaked at $102M in Q3 2018.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.